Needham & Company Reiterates Buy Rating, $205 Price Target on Alnylam Pharmaceuticals (ALNY) Despite Delay of vutrisiran, "Still Have High Confidence vutrisiran Will be Approved"
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $205.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
